In the last few years, mRNA has moved to the fore in the vaccine and cell and gene therapy fields, and as a result, its successful production for these downstream applications has never been more crucial. In this podcast episode, Róisin McGuigan , Editor, Nucleic Acid Insights , speaks to Ryan Lahr , Senior R&D Scientist, CELLSCRIPT, about design, production, and quality control of synthesized mRNA for translation in cells.
Mar 27, 2025•13 min•Season 4Ep. 3
Roisin McGuigan , Commissioning Editor, Nucleic Acid Insights , speaks to Stanley Crooke , Chairman, Founder and CEO, n-Lorem, about his long career and pioneering role in the antisense oligonucleotide (ASO) space, how RNA-targeting therapies are set to enter the mainstream, and his latest focus: making personalized, free-for-life ASO therapies available to nano-rare patient populations.
Mar 13, 2025•19 min•Season 4Ep. 2
Róisin McGuigan , Commissioning Editor, Nucleic Acid Insights , speaks to Ketaki Deshmukh , Senior Scientist, Novo Nordisk, about advanced characterization tools for LNPs, challenges in extrahepatic delivery, scalability issues, and the potential impact of AI and machine learning (ML) on future LNP development.
Feb 19, 2025•15 min•Season 4Ep. 1
Jokūbas Leikauskas , Editor, Cell & Gene Therapy Insights , speaks with OmniaBio Inc.’s Kenneth Harris , Chief Strategy Officer and Head of AI, Mitchel Sivilotti , President and CEO, and Anthony Rotunno , Senior Vice President and General Manager/Site Head, about the innovative advancements in cell and gene therapy, focusing on how AI, automation, and robotics are revolutionizing manufacturing processes by reducing costs, increasing production capacity, and ultimately, improving patient outc...
Jan 27, 2025•16 min•Season 3Ep. 12
Lauren Coyle , Commissioning Editor, Immuno-Oncology Insights , speaks with Banafshé Larijani , Director of the Centre for Therapeutic Innovation, University of Bath, about the development and application of a novel spatial mapping technology designed to improve cancer diagnostics and personalize treatment planning.
Dec 06, 2024•39 min•Season 3Ep. 11
Lauren Coyle , Commissioning Editor, speaks with Dhruv Sareen , Executive Director at Cedars-Sinai Biomanufacturing Center, and Johnathan Rodriguez , Quality Control Manager at Cedars-Sinai Biomanufacturing Center, about the roles of in-process controls, method validation, risk management, and automation in biomanufacturing. They will highlight strategies to ensure product safety, consistency, and regulatory compliance for cell and gene therapy products.
Dec 05, 2024•28 min•Season 3Ep. 10
For the first time in history, cell and gene therapy products are reaching the market in waves rather than in one’s and two’s, creating unprecedented challenges for pharma/biotech and healthcare sector stakeholders alike. David McCall , Senior Editor, BioInsights, speaks to Eric Faulkner , President and Chief Strategist, Passage Health Associates, about the chequered history of market access in the advanced therapies field, and what lessons can be taken forward to ensure a successful and sustain...
Sep 06, 2024•26 min•Season 3Ep. 9
David McCall , Senior Editor, BioInsights, spoke to Lee Brown , Healthcare Sector Global Team Leader, Third Bridge Group, on Tuesday, February 6, 2024 to gain his insights into the fast-moving market landscape of advanced therapies. The discussion outlines key recent news and strategic moves from prominent pharma and biotech companies in the field, as well as the prospects for specific technologies such as CRISPR-based genome editing and next-generation CAR-T therapies.
Jun 14, 2024•23 min•Season 3Ep. 8
Translating the therapeutic promise of cell and gene therapies into clinical reality relies on robust potency assays. However, designing assays that accurately reflect the complex mechanisms of these therapies can feel like chasing a moving target. Here, Charlotte Barker , Editor, Cell & Gene Therapy Insights , speaks with Giorgio Zenere , CMC technical project lead in the Global QC Technology Innovation Team, Kite Pharma, and Dirk Windgassen , Director of Analytical Development, Miltenyi Bi...
May 10, 2024•28 min•Season 3Ep. 7
Lauren Coyle , Commissioning Editor, Cell & Gene Therapy Insights , talks with Suman Subramanian , Head of Commercial Operations, Catalent Cell and Gene Therapy, to discuss the major achievements in the gene therapy market in 2023, with a focus on reliable manufacturing processes and strategies to enhance predictability while reducing waste in gene therapy manufacturing.
Apr 04, 2024•24 min•Season 3Ep. 6
Lauren Coyle , Commissioning Editor, Immuno-Oncology Insights , speaks with André Freitas , Senior Lecturer (University of Manchester) and Research Group Leader (Idiap Research Institute/National Biomarker Centre), about the intersection of generative AI and experimental cancer treatments, with a focus on clinical trials, regulatory considerations, and leveraging emerging technologies for a transformative impact in I-O.
Mar 18, 2024•44 min•Season 3Ep. 5
Lauren Coyle , Commissioning Editor, Immuno-Oncology Insights , speaks to Joe Chang , Clinical Thoracic Oncologist, MD Anderson Cancer Center, University of Texas, who discusses his team’s pioneering work in combining radiation therapy with immunotherapy for lung cancer treatment. He highlights the challenges and promises of optimizing radioimmunotherapy combinations, emphasizing the importance of personalized treatment approaches and collaboration across disciplines to improve patient outcomes....
Mar 12, 2024•15 min•Season 3Ep. 4
As excitement around the evolving field of mRNA continues to grow, there remain some fundamental questions to be answered. David McCall , Senior Editor, Nucleic Acid Insights , spoke with Monash University’s Colin Pouton , Professor of Pharmaceutical Biology and Angus Johnston , Associate Professor, ARC Future Fellow about the key limitations and unknowns of current mRNA delivery approaches, and critical areas for further research and innovation to propel the field forward....
Mar 11, 2024•45 min•Season 3Ep. 3
Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, interviews Katie Campbell, Postdoctoral Fellow, Cancer Research Institute, about her current research on genomics, transcriptomics, and spatial profiling to address challenges in the I-O field.
Mar 01, 2024•20 min•Season 3Ep. 2
With the potential for avian influenza to transmit and spread amongst humans, an effective vaccine to increase pandemic preparedness is a global priority. Charlotte Barker, Editor, Vaccine Insights, speaks with Mathilde Richard, Principal Investigator & Associate Professor at Erasmus MC, about investigating antigenic evolution of avian influenza viruses, developing better vaccines, and the need for proactive measures to ensure global preparedness in the face of evolving influenza threats....
Feb 27, 2024•24 min•Season 3Ep. 1
Lauren Coyle, Editor, Immuno-Oncology Insights , speaks to Yvonne McGrath, Chief Scientific Officer, iTeos Therapeutics, about the current and emerging novel targets and pathways for the use of cancer therapy in the I-O field with a focus on small molecules and antibody targets.
Dec 04, 2023•17 min•Season 2Ep. 16
Lauren Coyle , Editor, Immuno-Oncology Insights, speaks with Raoul Santiago , Clinical Investigator and Associate Professor of Pediatric Hematology and Oncology, University Hospital Center, Laval University, to discuss the role of multiomics in the I-O setting and how these tools can be leveraged to improve pediatric cancer care.
Nov 02, 2023•20 min•Season 2Ep. 15
The cell and gene therapy space poses a number of unique challenges when it comes to facility design. In this episode, Róisin McGuigan , Editor, BioInsights, speaks to Yposkesi’s Louis-Marie De Montgrand and Morad El Gueddari to discuss the key considerations for designing an advanced therapy manufacturing facility that can meet the needs of future commercial demand. To read this interview and access lots more content, visit the Cell and Gene Therapy Insights website....
Oct 10, 2023•29 min•Season 2Ep. 14
In this episode, Charlotte Barker, Editor, BioInsights, will be discussing the future of AAV-based gene therapy manufacturing with Elie Hanania, VP of Process Development Viral Vector Technologies at Avid Bioservices, and Ratish Krishnan, Senior Strategy Consultant at Merck Life Sciences.
Sep 13, 2023•22 min•Season 2Ep. 13
The application of lipid nanoparticles (LNPs) as a non- viral delivery system for advanced therapies, in conjunction with RNA-based medicines, is set to revolutionize the field. In this episode, David McCall, Senior Editor, BioInsights, speaks to Adrian Bot, Chief Scientific Officer and Executive Vice President of R&D, Capstan Therapeutics, about the potential of these tools to drive the burgeoning in vivo cell therapy space in particular, and the broader gene medicine field in general....
Aug 30, 2023•20 min•Season 2Ep. 12
David McCall, Senior Editor, BioInsights, speaks to Geeta Vemuri, Founder and Managing Partner, Agent Capital, about her VC company's portfolio of advanced therapy investments, and the keys to obtaining funding in a difficult environment. (From an interview conducted on February 22nd, 2023).
Aug 22, 2023•15 min•Season 2Ep. 11
While attractive from an initial cost perspective, performing early development in a cell culture substrate that does not match a therapy’s final manufacturing platform can have critical implications on development timelines. In this podcast, Charlotte Barker, Editor, BioInsights, speaks to Dalip Sethi, Director of Scientific Affairs, Terumo BCT, about best practices for scaling up cell culture substrate.
Aug 16, 2023•19 min•Season 2Ep. 10
In this episode, Róisin McGuigan, Editor, Immuno-Oncology Insights , speaks with Eran Ophir, Chief Scientific Officer, Compugen, and Yaron Turpaz, Senior Vice President and Senior Advisor, Data and Informatics Solutions, Compugen, about the advantages of using multiomic and computational approaches for the discovery of novel targets and mechanisms of action (MoA) of novel drug candidates in immuno-oncology.
Aug 08, 2023•19 min•Season 2Ep. 9
Charlotte Barker (Editor, BioInsights) speaks with Curate Biosciences’ CEO David Backer and CTO Tony Ward about the need for CAR-T cell therapy manufacturing to evolve, and how a new cell separation technique could boost efficiency.
Jul 26, 2023•24 min•Season 2Ep. 8
Charlotte Barker, Editor, Vaccine Insights , speaks with Ed Lavelle, Professor, Trinity College Dublin, about our growing understanding of adjuvant mechanisms, his work on developing mucosal vaccines, and why size matters for nanoparticles’ adjuvant effects.
Jul 26, 2023•14 min•Season 2Ep. 7
In this episode Róisin McGuigan (Editor, BioInsights) speaks to Paul Byrne (Senior Director, Genomics, ProtaGene) about the evolution of the gene therapy field, with a specific focus on the complexities posed by biodistribution, vector shedding, and transgene expression in gene therapy development.
Jun 09, 2023•31 min•Season 2Ep. 6
Non-viral methods for ex vivo cell & gene therapy: is the future non-viral? In this episode, Valeria Annibaldi and Andrea Toell discuss the types and benefits of non-viral methods for ex vivo cell and gene therapy in addition to the readiness of electroporation-based technologies for use in GMP manufacturing. To read this interview and access lots more content, visit the Cell and Gene Therapy Insights website...
May 31, 2023•22 min•Season 2Ep. 5
Cell therapy clinical trials pose a variety of complex challenges. Logistics with cell harvesting, manufacturing, shipments back to sites, patient safety, changing standard-of-care treatments, and patient enrolment due to competing trials can all impact study timelines. In this episode, Vito Romita and Jai Balkissoon outline key obstacles for developing cell therapies in oncology, and provide their insights on overcoming them in order to increase patient access and design safer trials. To read t...
Apr 17, 2023•25 min•Season 2Ep. 4
The tangential flow filtration (TFF) unit operation in viral vector manufacturing is a critical step on the path to commercialization. In this episode, Merck viral vector experts Ratish Krishnan and Akshat Gupta discuss best practices – and common misconceptions – when establishing process conditions and utilizing different TFF device formats.
Apr 06, 2023•18 min•Season 2Ep. 3
Current options for cryogenic storage containers in cell and gene therapy are limited in their functionality as the industry continues to move towards increased scale and automation. In this episode, Sean Werner and Alex Sargent address specific challenges with current optionality, while also considering what future innovations in this area might look like. To read this interview and access lots more content, visit the Cell and Gene Therapy Insights website...
Mar 22, 2023•18 min•Season 2Ep. 2
